MBRX

Conviction 12HealthcareScan · Mon, Aug 10, 2026

MBRX$0.4318+5.45%

ResistanceSupportVol 14Insider buy

Vol MA14 2.8M

May 11May 28Jun 16Jul 6Jul 23Aug 10

Moleculin Biotech, Inc.PHARMACEUTICAL PREPARATIONSwww.moleculin.com ↗

Price0.4318

Change+5.45%

Gap+1.12%

Rel volume0.25×

Avg volume1.99M

Avg $ vol1.03M

SMA 201.45

SMA 502.18

SMA 2002.66

Price vs 50-80.17%

Price vs 200-83.77%

MA stackbearish

50/200 cross—

Supertrenddown · 1.02

RSI (14)19

MACD hist-0.11

MACD cross—

Stoch %K / %D13 / 12

ADX (14)40

+DI / −DI11 / 53

RSI divergence—

MACD divergence—

ATR %+48.19%

ADR %23.82%

52w high7.71

52w low0.2727

From 52w high-94.40%

Above 52w low+58.34%

New 52w highNo

SqueezeOff

Bollinger width226.09%

%B0.19

Donchian pos12.41%

Donchian high2.34

Donchian low0.1614

AVWAP (52w high)2.15

vs AVWAP high-79.94%

AVWAP (52w low)0.3711

vs AVWAP low+16.36%

OBV trendDown

Chaikin MF (20)-0.27

Today vs 20d0.25×

Avg vol (14d)2.8M

Avg vol (20d)1.99M

Avg $ vol (20d)1.03M

Market cap2.3M

RS 3m (vs SPY)-89.25%

RS 6m (vs SPY)-103.64%

RS line new highNo

Trend template3/8

Technical rank5.2

1 week+1.60%

1 month-81.06%

3 months-82.52%

6 months-89.98%

1 year-36.26%

YTD-88.07%

P/E-0.07

P/B0.15

P/S—

P/FCF-0.10

EPS-0.5900

Div yield—

ROE-221.04%

ROA-143.65%

Debt/Eq—

Current1.38

EV/EBITDA0.32

Gross margin—

Net margin—

Rev growth—

EPS growth-28.84%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-8.01M

Revenue0

Net income-12.85M

Gross profit—

Free cash flow-22.73M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out5.34M

Employees17

ListedThu, Jun 2, 2016

Free float4.93M

Float %92.4%

Short interest1.05M

Days to cover4.3d

Short volume56.3%

Squeeze score72 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction12 / 100

Pattern quality—

Tech rank5.2 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.43

Support0.2534

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in MBRX

All disclosures →

No recent disclosed trades by Congress in MBRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MBRX · 6 buys

Insider	Side	Shares	Value	Traded	Filed
Foster Jonathan P. Chief Financial Officer · Common Stock · 2026-08-03	Buy	293.33K	—	2026-08-03	2026-08-05
Foster Jonathan P. Chief Financial Officer · Series I Warrants · 2026-08-03	Buy	880K	—	2026-08-03	2026-08-05
KLEMP WALTER V CEO and President · Common Stock · 2026-08-03	Buy	533.33K	—	2026-08-03	2026-08-05
KLEMP WALTER V CEO and President · Series I Warrants · 2026-08-03	Grant	1.6M	—	2026-08-03	2026-08-05
PICKER DONALD H Chief Science Officer · Common Stock · 2026-08-03	Buy	173.33K	—	2026-08-03	2026-08-05
PICKER DONALD H Chief Science Officer · Series I Warrants · 2026-08-03	Buy	520K	—	2026-08-03	2026-08-05

SEC filings

EDGAR filings in MBRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.